Charles Greenfield
Neurology · Dallas, TXNPI 1477528305
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 193 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,747 and has fallen 98.7% since, to $23 in 2025.
Across 193 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$661
- Sunovion Pharmaceuticals Inc.$418
- EMD Serono, Inc.$296
- Genentech USA, Inc.$277
- UCB, Inc.$226
- Sanofi$219
- plus $1K from 29 others
Across 19 payments — averaging $18,513 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$218K
- Genentech, Inc.$129K
- Merck$3K
- Novartis$2K
- Mallinckrodt Enterprises LLC$321
What the payments were for
- Speaking & faculty fees$201%
- Food & beverage$3,44299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $661 |
| Sunovion Pharmaceuticals Inc. | 24 | $418 |
| EMD Serono, Inc. | 18 | $296 |
| Genentech USA, Inc. | 18 | $277 |
| UCB, Inc. | 13 | $226 |
| Sanofi | 12 | $219 |
| Novartis | 12 | $197 |
| Amgen | 5 | $124 |
| Biogen | 6 | $103 |
| Jazz Pharmaceuticals Inc. | 1 | $96 |
| AstraZeneca | 5 | $92 |
| SK Life Science, Inc. | 6 | $90 |
| Grifols USA, LLC | 4 | $75 |
| Upsher-smith Laboratories LLC | 4 | $74 |
| Mallinckrodt Enterprises LLC | 3 | $65 |
| Merz North America, Inc. | 1 | $42 |
| Kyowa Kirin, Inc. | 2 | $37 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Avanir Pharmaceuticals, Inc. | 2 | $34 |
| Tanabe Pharma America, Inc. | 2 | $29 |
| Pfizer | 2 | $29 |
| Lilly USA, LLC | 2 | $27 |
| Adamas Pharmaceuticals, Inc. | 1 | $22 |
| Acorda Therapeutics, Inc | 1 | $20 |
| Johnson & Johnson | 2 | $20 |
| CSL Behring | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $17 |
| GE HealthCare | 1 | $15 |
| Greenwich Biosciences, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
| Harmony Biosciences LLC | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Duopa$104
How this compares
$3,463 in reported general payments places this provider in the 55th percentile of 1,246 neurology providers in Texas.
Other neurology in Dallas
- Nirav PavasiaDallas$1.4M
- Benjamin GreenbergDallas$773K
- Waleed El-FekyDallas$587K
- Adnan SubeiDallas$477K
- Steven HerzogDallas$461K
- Priyanka ChaudhryDallas$329K
- Deborah FriedmanDallas$284K
- Mark AlbertsDallas$212K
- Aanchal TanejaDallas$169K
- Salman BhaiDallas$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.